Voyager Therapeutics to Present at Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day

CAMBRIDGE, Mass., March 14, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Steven Paul, M.D., president and chief executive officer, will present at the Alliance for Regenerative Medicine’s 4^th Annual Cell & Gene Therapy Investor Day on Tuesday, March 22, 2016 in New York City as follows:

Event: Voyager Therapeutics Company Overview
Time: 11:30 – 11:45 a.m. ET

Event: Optimization of Gene Therapies - Consideration of Key Platform Technologies Panel
Time: 3:10 – 4:05 p.m. ET

A live-streaming webcast of all panels and company presentations will be available at www.arminvestorday.com/webcast. Archived webcasts will be published on the event’s website shortly after the conference.

About ARM’s Cell & Gene Therapy Investor Day

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.

Contact:	
Investor Relations:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected] 

Media:
Katie Engleman
Pure Communications, Inc. 
910-509-3977
[email protected]